Condition: Melanoma · Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
This is a Phase II, open-label, randomized, multi-center study to assess the efficacy and safety of IBI363 monotherapy compared to Pembrolizumab in the treatment of patients with unresectable locally advanced or metastatic mucosal or acral melanoma who had not previously received systemic therapy.
This description comes directly from the study's public registry record.
Xiuzhi Yu · 0512-69566088 · xiuzhi.yu@innoventbio.com
Always discuss trial participation with your own doctor first.
| First Affiliated Hospital of Anhui Medical University | Hefei, Anhui, China | Recruiting |
| Beijing Jishuitan Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Peking University Cancer Hospital & Institute, Beijing, China, | Beijing, Beijing Municipality, China | Recruiting |
| Chongqing University Cancer Hospital | Chongqing, Chongqing Municipality, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Affiliated Tumor Hospital of Guangxi Medical University | Nanning, Guangxi, China | Recruiting |
| Fourth Hospital of Hebei Medical University | Shijiazhuang, Hebei, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
| The Third people's hospital of Zhengzhou | Zhengzhou, Henan, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Hena, China | Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06797297